Skip to main content

Table 2 Characteristics of included studies

From: A systematic review and meta-analysis of risks and benefits with breast reduction in the public healthcare system: priorities for further research

Author
Year
Country
Study
design
Study duration (years)
Follow-up (mean number of months)
Study groups;
Intervention and control treatment
Patients (n) Mean age
(years)
Mean BMI Smokers (n, %) Definition of breast hypertrophy Resection weight, g (mean)
Araujo
2014
Brazil [40]
RCT
(cost-utility)
SD: NR
FU: 6
I: Breast reduction; conventional technique (inverted T-shaped scar and medial pedicle technique in most patients)
C1: No treatment
60
I: 30
C: 30
 BMI >30 excluded)
I:32
C:35.5
(median)
I: 26.4
C: 26.3 (median)
NR Classification by Sacchini et al 1200
Beraldo
2016
Brazil [41]
RCT
(same RCT as above)
As above As above As above As above As above NR As above As above
Freire
2007
Brazil [37]
RCT SD: NR
FU: 6
I: Breast reduction; rigid outlining, transferring to opposite breast, preservation of papillary-areola complex using fatty dermal pedicle. Inverted T-shaped scar
C1: Waiting list for reduction mammaplasty 6 months later
100
I: 50
C: 50
 BMI> 30 excluded)
31.95 25.56 0 NR 1052.19
Neto
2008
Brazil [36]
RCT
(same RCT as above)
SD: 2.08
FU: 6
As above As above As above As above 0 NR As above
Iwuagwu 2006
UK [39]
RCT SD: 1.67
FU: 4
I: Bilateral breast reduction with an inferior pedicle
C2: Physiotherapist-instructed upper body exercise 3 times/week while on wait list for surgery
73
I: 36
C: 37
No restriction related to BMI
39.15 28.5 NR Bra cup size E or more in conjunction with symptoms in the upper body associated with mammary hypertrophy NR
Iwuagwu 2006
UK [31]
RCT
(same RCT as above)
As above As above 73
I: 40
C: 73
As above As above NR As above NR
Saarinemi 2008
Finland [34]
RCT SD: NR
FU: 6.35
I: Breast reduction
C1: Waiting list
82
I: 40
C: 42
No restriction related to BMI
46.35 29.65 NR NR 670
Saarinemi 2009
Finland [57]
RCT
(same RCT as above)
As above As above As above As above As above NR NR As above
Andrade
2018
Brazil [42]
Non-randomized controlled study SD: 1
FU: 6–12
I: Breast reduction
C1: Waiting list
100
I: 50
C: 50
BMI < 30
I: 33
C: 31 (median)
I: 27
C: 26
(median)
NR “By the criteria by Sacchini et al. and Franco & Rebello” 1107
Hermans
2005
Netherlands [43]
Non-randomized controlled study SD: 2
FU: 25.4 (mean, intervention group)
I: Breast reduction, modified Strömbäck procedure with mediocranial pedicle
C1: Waiting list
165
I:94
C:71
BMI < 30
37.3 25.65 NR Cup size D or above 536
Janik
2019
Poland [62]
Non-randomized controlled study SD: 0.25 months
FU: 23.56 (mean)
I: Breast reduction
C1: Waiting list
102
I:75
C: 27
38 27.5 24% NR NR
Fairchild
2020
USA [32]
Case series SD: 7
FU: 1
I: Breast reduction 283 (not obese, (BMI < 30);Not included because BMI < 35 not separately reported: 259 (obese, BMI > 30, range 32–38) 17
(median)
26 (median) NR NR NR
Nelson
2014
USA [33]
Case series SD; 7
FU: 1
I: Breast reduction 2074 (BMI < 30);
1308 (BMI 30–34.9)
NR NR 10% NR NR
Simpson
2019
USA [49]
Case series SD: 10
FU: 1
I: Breast reduction 8180 (BMI < 30);
4656 (BMI 30.1–35)
NR
(solely reported for total cohort)
NR
(solely reported for total cohort)
NR NR NR
Shakespeare
1999
UK [38]
Qualitative SD: 2,75
FU: 24
I: Breast reduction 110 35 NR NR NR NR
  1. RCT randomised controlled trial, NR not reported, SD study duration, FU follow-up, BMI body mass index, HRQoL health-related quality of life